The Israeli biotechnology firm hopes that a successful outcome of the study with Centre Léon-Bérard will raise its profile among oncologists.
Using genomic data from large cancer cell line collections, investigators identified versions of spliced genes that spell better or worse drug response.
Investigators developed a pooled method for simultaneously sequencing RNA in bulk sets of samples being profiled by high-throughput screening assays.
The company combines screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
Researchers screened cancer cell lines to detect mutations and drug combinations that might sensitize tumors to drugs that impair anti-apoptosis proteins.
Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database to uncover relationships between genetic variation and human health outcomes.
Horizon CombinatoRx will be paid $750,000 for the five-month project.
NEW YORK (GenomeWeb) – The National Institutes of Health has awarded $17 million to fund 11 research groups seeking to develop 3-D human tissue chips that can be used to predict drug safety and effectiveness, NIH said today.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.